Sanofi, GSK variant-specific COVID shot found effective against Omicron

Posted on AllSides June 24th, 2022
From The Center
REUTERS/Benoit Tessier

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi (SASY.PA) and GSK (GSK.L) has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

When used in people who...

Read full story

AllSides Picks Tessier

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right